Stem cell therapy using UC-MSCs and DFPP therapy for ALS
Amyotrophic lateral sclerosis (ALS) is a fatal malignant neurodegenerative disease characterized by the progressive degeneration of motor neurons in the brain, brainstem and spinal cord. Patients often develop muscle weakness, stiffness, swallowing problems, speech changes, respiratory weakness and reduced mobility as motor neurons slowly lose function. ALS is multifactorial as it does not stem from a single pathway. Various mechanisms have been described to drive the progression of ALS: oxidative stress, glutamate excitotoxicity, mitochondrial dysfunction, protein aggregation, and neuroinflammation.
ALS is a neurodegenerative disease with an inflammatory component, many patients and clinicians are investigating advanced supportive therapies. Among those stem cell therapy with UC-MSCs and Double Filtration Plasmapheresis or DFPP therapy. It should be emphasised that these options are not a treatment for ALS, but may qualify as adjuncts in selected patients monitored by clinicians.
An Overview of UC-MSCs in ALS Therapy
UC-MSCs, also known as umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs), have been the subject of extensive research in regenerative medicine due to their ability to secrete various biologically active molecules including cytokines, growth factors, exosomes and other paracrine factors. In ALS, UC-MSCs are mostly not expected to directly replace damaged motor neurons. They are most likely more useful for cell-to-cell communications, immune modulation, anti-inflammatory signaling and maintenance of the neurological microenvironment.
Although clinical studies on the use of mesenchymal stem/stromal cells in ALS have given safety signals and some efficacy in carefully selected patients, outcome is not homogeneous, and large controlled studies are awaited. A study of Wharton s jelly-derived MSCs in ALS reported that no serious ADR occurred, but variation among responders was seen with some patients qualifying for a slower progression and others remaining at least stable or having faster progression.
Relevance of UC-MSCs for ALS
Neuroinflammation Support
Neuroinflammation is one of the primary biological processes associated with ALS propogation. Nevertheless, UC-MSCs may act on paracrine signaling which may lead to the regulation of inflammatory signals that can help in establishing a less hostile environment around motor neurons.
Immune Modulation
Although ALS is not traditionally classified as an autoimmune disease, immune dysregulation and inflammatory immune activation are likely involved in disease progression. UC-MSCs could support a better tolerant immune milieu and might have the ability to interact with immune cells.
Neurotrophic and Tissue-Supportive Signaling
UC-MSCs can secrete growth factors and extracellular vesicles facilitating cell survival signalling, intercellular communications for tissue repair and microenvironment homeostasis. This is probably applicable in ALS, where chronic stress acts on motor neurons.
Quality of Life Goals Facilitation
The rationale for the UC- MSC was to provide adjunctive support to selected patients in the hope of maintaining function, supporting comfort, minimizing inflammatory burden, and optimizing overall wellness while receiving standard of care for ALS. Research into cellular therapies for ALS is promising but still controversial, particularly in terms of long-term efficacy and appropriate patient selection.
What Is DFPP Therapy?
Double filtration plasmapheresis is a blood filtration technique that separates plasma and selectively filters larger circulating moieties. In some selected immune-mediated and inflammatory conditions, it is used to remove certain circulating factors like immunoglobulins, antibodies, immune complexes, and inflammatory mediators.
The use of DFPP in neuroimmune disorders has been explored due to its ability to decrease immunoglobulin and also culprit antibody levels. In a 2024 retrospective analysis, researchers found that DFPP could reduce immunoglobulin levels and antibody titers in several neuroimmune diseases with mostly minor and no serious adverse events.
Possible Benefits of DFPP Therapy for ALS Care
Reducing Circulating Inflammatory Burden
ALS is characterized by systemic and neurological inflammatory stress. The interview also states that DFPP have a reduction of some selected circulating inflammatory or immune-related factors which could help to stabilise an internal environment.
Preparing the Body Prior to UC-MSC Infusion
An essential justification for DFPP versus UC-MSC therapy is “preparation.” DFPP may provide a physiological milieu more conducive to UC-MSC infusion by lowering specific circulating inflammatory mediators.
Supporting Immune and Plasma Balance
Long-term plasma cleansing with DFPP may decrease plasma components that deliver immune activation or inflammatory load. That does not mean DFPP can treat motor neuron degeneration directly, but it has the potential to serve as an adjunctive medical treatment.
Optimizing the Internal Environment
The internal environment counts for regenerative support. For instance, a highly inflammatory or oxidative stress burdened tissue may exhibit poor cellular responsiveness to different signaling events. This scenario may explain how DFPP could theoretically correct this background condition before UC-MSC treatment.
For the reasons above we reported a mechanism of how DFPP therapy works and showed that combining DFPP with UC-MSCs may effectively elevate severity of ALS.
This combined strategy of DFPP therapy + UC-MSC stem cell therapy for ALS is strongly supported by the concept of the two-step support.
DFPP therapy also notably decreases selective hindering factors in the circulation system particularly those possessing pro-inflammatory results and include immune-related aspects. This can decrease the biological load in the blood and help prepare the body for the next step.
Second, UC-MSCs might offer regenerative and immunomodulatory signaling. Through facilitating the optimization of the plasma environment, UC-MSCs may have a more favorable supportive condition to communicate with immune cells, inflammatory pathways and damaged tissue environments.
In lterms of , DFPP may help prime the internal milieu and UC-MSCs are implicated to provide extrinsic biological cues. When the treatment includes not only infusion of cells but also improvement of body condition prior to infusion, this combination can be particularly useful.
Figure 1: Proposed Two-Step Supportive Strategy of DFPP and UC-MSCs in ALS Care
Combined Potential Benefits
One combined therapy of UC-MSCs plus DFPP for ALS may support:
Improved local microenvironment prior to UC-MSC infusion
Decreased levels of specific circulating inflammatory and immunity-related factors
More suitable biology for UC-MSC paracrine signaling
Support for neuroinflammation balance
Support for immune regulation
Early tissue-repair and neurotrophic signaling support
Comorbidities and QoL with ALS care
Patient Selection Is Important
However, not everyone with ALS is an ideal candidate for this method. This involves a review of the patients diagnosis, disease stage, respiratory function, swallowing status, independence in mobility as well as markers for inflammation and organ function (Kidney and Liver), potentially ongoing infection screening, medication history, nutritional intake and physical condition.
Patients having active exposure or with unstable vital signs, severe anemia, bleeding risk, very advanced respiratory compromise and/or major medical instability will need to be excluded and referred for further evaluation also prior to the administration of DFPP or UC-MSC based support.
Conclusion
The role of UC-MSCs in ALS was mainly involved with immune modulation, supporting neuroinflammation, paracrine signaling and microenvironmental support. As such, DFPP therapy is designed to deázirry selected regulators of the circulatory immune-inflammatory products to modify low-grade systemic inflammation prior to cellular immunotherapy application.
Moreover, both therapies may work synergistically to create a more effective regenerative environment with DFPP optimizing the internal condition and UC-MSCs providing supportive regenerative signals. Together this approach may provide a more robust supportive measure in selected patients with ALS. It is never an unconditional cure-all, a substitute for proper neurology care or something to pursue without sober advice and careful consideration.